Billionaire Cliff Asness’ Top 10 Healthcare Stock Picks
Cliff Asness is a billionaire investor and the co-founder and chief investment officer of AQR Capital Management, a quantitative hedge fund.
Posts Tagged ‘NASDAQ:NBIX’
10 High Growth NASDAQ Stocks to Buy Now
On June 25, Ryan Detrick, Carson Group Chief Market Strategist, appeared on CNBC's 'Squawk Box' to discuss the latest market trends.
10 High Growth Stocks to Buy Right Now
On June 23, Chris Harvey of CIBC and Adam Parker of Trivariate joined CNBC's 'Closing Bell Overtime' to talk about the day's market action.
Is Neurocrine Biosciences, Inc. (NBIX) A Good Stock To Buy Now?
Is NBIX a good stock to buy? We came across a bullish thesis on Neurocrine Biosciences, Inc. on TradersPro’s Substack.
15 Most Promising Stocks to Buy Right Now
Promising quality growth stocks are getting more attention as investors look for companies where growth expectations are still backed by earnings momentum, not just market excitement...
15 High Growth Stocks to Buy and Hold for the Next Decade
High-growth stocks are getting more attention as investors look beyond the first wave of AI winners and try to identify companies that can still compound earnings over a longer...
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2026 Earnings Call Transcript
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2026 Earnings Call Transcript May 5, 2026Neurocrine Biosciences, Inc. beats earnings expectations.
Neurocrine Biosciences (NBIX) Announces First Presentation of New Two-Year Data From Phase 3 CAHtalyst® Adult Study
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the best drug stocks to buy according to analysts. On April 22, Neurocrine Biosciences, Inc.
9 Best Drug Stocks to Buy According to Analysts
On April 27, Jurrien Timmer, director of global macro at Fidelity Investments, appeared on CNBC to talk about the market and oil prices, and how necessary it is for oil prices...
Truist Lowers Neurocrine Biosciences, Inc.’s (NBIX) PT Following 2026 Outlook Update
TheFly reported on February 17 that Truist reduced its price target on NBIX to $140 from $169 and maintained a Buy rating on the stock. The increase came after management...
7 Oversold Pharma Stocks to Buy Now
In 2024, the pharmaceutical sector in the United States was valued at $634.32 billion, and by 2030, it is expected to have grown to $883.97 billion.
Needham Bullish on Neurocrine Biosciences, Inc. (NBIX) Pipeline Amid 2026 Growth Expectations for Crenessity and Ingrezza
TheFly reported on February 12 that Needham lowered its price target on NBIX to $185 from $187 and maintained a Buy rating. The company is still hopeful about Crenessity...
7 Most Promising Psychedelic Stocks According to Hedge Funds
The psychedelic industry is poised to have a significant "second wave," transforming from a speculative, counterculture-driven movement into a recognized cornerstone of the US...
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2025 Earnings Call Transcript
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2025 Earnings Call Transcript February 11, 2026Neurocrine Biosciences, Inc. misses on earnings expectations.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q3 2025 Earnings Call Transcript
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q3 2025 Earnings Call Transcript October 28, 2025Neurocrine Biosciences, Inc. beats earnings expectations.
Should You be Optimistic on Neurocrine Biosciences (NBIX)?
PGIM, an investment management company, released its “PGIM Jennison Health Sciences Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here.
What Does Wall Street Think About Neurocrine Biosciences (NBIX)?
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the best drug stocks to buy right now.
12 Best Drug Stocks to Buy Right Now
The Food and Drug Administration announced a crackdown on misleading drug company ads, stating that it intends to send out thousands of warning letters along with around 100 cease...
Neurocrine Biosciences, Inc. (NBIX) Beats Estimates on Neurology Drug Demand, Expands Payer Access
Neurocrine Biosciences, Inc.
11 Best Pharma Stocks to Invest in for the Long Term
According to a recent White House announcement, President Trump wrote letters to 17 major pharmaceutical companies outlining the actions they could take to bring the prices of...
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q2 2025 Earnings Call Transcript
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q2 2025 Earnings Call Transcript July 30, 2025Neurocrine Biosciences, Inc. beats earnings expectations.
Neurocrine Biosciences Grows Pipeline While Maintaining Steady Investor Confidence
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) develops therapies targeting neurological, neuroendocrine, and neuropsychiatric disorders.
Morgan Stanley Lifts PT on Neurocrine Biosciences (NBIX) to $150 From $148, Keeps Overweight Rating
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the best strong buy healthcare stocks to buy now.
10 Best Strong Buy Healthcare Stocks to Buy Now
On July 21, Jared Holz, Mizuho health care sector strategist, appeared on CNBC's 'The Exchange' to talk about whether any opportunity plays exist within the healthcare sector, ...
11 Best Long Term Low Risk Stocks to Invest in
The uncertainty prevailing in the current market environment demands a closer examination beyond just earnings reports and share price trends when seeking a worthy investment.
Untapped Patient Base, Ingrezza Growth Keep Neurocrine (NBIX) on Guggenheim’s Buy List
Neurocrine Biosciences Inc. (NASDAQ:NBIX) is one of the 11 best debt-free stocks to invest in right now.
11 Best Debt-Free Stocks to Invest in Right Now
It is widely understood that employing debt to fund operations can act as a powerful financial tool. But debt doesn't come without its trade-offs.
Guggenheim Maintains Buy Rating on Neurocrine Biosciences Following Investor Meeting
On June 4, analysts at Guggenheim reiterated their Buy rating for Neurocrine Biosciences, Inc. (NASDAQ:NBIX), keeping their price target at $165.
15 Small-Cap Healthcare Stocks Hedge Funds Are Buying
The U.S. healthcare sector has performed better in 2025 compared to the broader market.
Billionaire Ken Griffin’s 10 Midcap Stock Picks with Huge Upside Potential
Ken Griffin, the founder of Citadel, is an influential albeit controversial figure in the investment industry.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2025 Earnings Call Transcript
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2025 Earnings Call Transcript May 5, 2025Neurocrine Biosciences, Inc. misses on earnings expectations.
Billionaire Cliff Asness’ 10 Stock Picks with Huge Upside Potential
Cliff Asness, the founder, managing principal, and chief investment officer of AQR Capital Management, is a well-known figure in the world of finance.
15 Best Biotech Stocks to Buy According to Billionaires
Although biotech stocks had a "challenging" year in 2024, JPMorgan believes that some of the industry's companies could see significant growth in the months to come.
15 Best Fast Growth Stocks To Buy Right Now
In the fourth quarter of 2024, the US Gross Domestic Product (GDP) expanded at an annual rate of 2.3%, slightly below market expectations of 2.7% and a deceleration from the 3...
10 Top Insider Stock Buys And Sells In January
Ever heard of the “January effect?” In case you haven’t, a “January effect” is considered a phenomenon in the stock market where stock prices, most commonly of small...
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2024 Earnings Call Transcript
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2024 Earnings Call Transcript February 6, 2025Neurocrine Biosciences, Inc. misses on earnings expectations.
12 Best Low Risk High Growth Stocks to Invest In
In the past few days, the reintroduction of tariffs by the US government has been a significant factor influencing market dynamics.
10 High Growth Healthcare Stocks to Invest in Now
During lean economic times, investing in healthcare stocks is generally regarded as defensive.
12 Most Profitable Pharmaceutical Stocks Right Now
Healthcare, which includes numerous businesses that offer patient care, conduct research and development of novel treatments, and design, produce, and distribute diagnostic tools...
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q3 2024 Earnings Call Transcript
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q3 2024 Earnings Call Transcript October 30, 2024Neurocrine Biosciences, Inc. misses on earnings expectations.
10 Most Promising Biotech Stocks According to Hedge Funds
Biotechnology stocks are known for their high risk, making them some of the most volatile in the market.
10 Best Aggressive Growth Stocks to Buy According to Hedge Funds
If you're putting money in the stock market, it's more likely than not that growth is the thing that's on your mind.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q2 2024 Earnings Call Transcript
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q2 2024 Earnings Call Transcript August 1, 2024Neurocrine Biosciences, Inc. misses on earnings expectations.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2024 Earnings Call Transcript
Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS is $0.4189 EPS, expectations were $1.04. Neurocrine Biosciences, Inc.
Insiders Are Dumping These 5 Healthcare Stocks
This article presents an overview of Insiders Are Dumping These 10 Healthcare Stocks. For a detailed overview of such stocks, read our article, Insiders Are Dumping These 10...
5 Best Small-Cap Growth Stocks to Invest In
In this piece, we will take a look at the five best small-cap growth stocks to invest in.
Wall Street Analysts Just Trimmed Price Targets for These 10 Stocks
In this article, we will discuss the 10 stocks whose price targets were recently trimmed by analysts.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2023 Earnings Call Transcript
Operator: Good day and welcome to Neurocrine Biosciences’ year-end and fourth quarter results call. At this time, all participants are in a listen-only mode.
Growth Stock Portfolio: 15 Companies with At Least 30% Annual Growth Rates
In this article, we will take a look at the 15 stocks with at least 30% annual growth rates to consider for a growth stock portfolio.
Hedge Fund Resource Center
